icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Sight Sciences to Showcase OMNI Surgical System's Long-Term Efficacy at AGS 2025

Marcus LeeMonday, Feb 24, 2025 4:14 pm ET
2min read

Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company, is set to present comprehensive clinical data on its OMNI® Surgical System at the 2025 American Glaucoma Society (AGS) Annual Meeting. The meeting, scheduled for February 26 to March 1, 2025, in Washington, D.C., will provide a platform for Sight Sciences to highlight the long-term safety and effectiveness of the OMNI Surgical System across diverse patient populations and disease severities.

The OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG). The system enables an implant-free, ab interno MIGS procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with glaucoma.

At the AGS 2025 Annual Meeting, Sight Sciences will present multiple presentations showcasing new data on the clinical effectiveness and safety of the OMNI Surgical System. These presentations will feature data curated by Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD). The data stems from a partnership between Verana Health and the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), which is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the United States.

One of the key presentations, titled "Systematic Review and Meta-analysis of Clinical, Economic, and Humanistic Evidence for the Canaloplasty/Trabeculotomy Surgical System (CTSS) in Open-Angle Glaucoma Treatment," will be presented by Sameh Mosaed, MD, UC Irvine. This meta-analysis of 22 unique studies, including 2,379 eyes, concluded that OMNI and predecessor devices (CTSS) consistently reduced intraocular pressure ("IOP") and decreased the need for medication up to 36 months. The data also showed that both standalone and combined treatment effectively reduced IOP and medication use for up to 24 months.

Another presentation, titled "What's your sign? GEMINI," will be given by Mona Kaleem, MD, Johns Hopkins School of Medicine. This presentation will recognize the prospective GEMINI study as a landmark trial in glaucoma, demonstrating the safety and efficacy of the OMNI Surgical System in treating primary open-angle glaucoma in adult patients.

A third presentation, titled "Standalone Canaloplasty and Trabeculotomy Outcomes for Phakic and Pseudophakic Eyes: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)" will be presented by Leon W. Herndon Jr., MD, Duke University. This study, based on real-world data from the IRIS Registry, will provide valuable insights into the performance of the OMNI Surgical System across diverse patient populations and disease severities.

The breadth of clinical data presented at AGS highlights the long-term safety and effectiveness of the OMNI Surgical System in a wide range of glaucoma patients, including diverse patient populations and different disease severities. These new findings reflect Sight Sciences' commitment to advancing glaucoma care and providing physicians with effective treatment options that ultimately benefit patients by reducing their dependence on medications and improving their quality of life.



In conclusion, the upcoming AGS 2025 Annual Meeting presents an excellent opportunity for Sight Sciences to showcase the long-term efficacy and safety of the OMNI Surgical System. The company's commitment to advancing glaucoma care and providing effective treatment options for patients is evident in the comprehensive clinical data it will present at the meeting. Investors and healthcare professionals alike should pay close attention to these developments, as they may have significant implications for the future of glaucoma treatment.
Comments

Add a public comment...
Post
User avatar and name identifying the post author
KAYLA
02/24

A big thank you to the amazing Susan Brookes for helping me grow my wealth through smart investing!
Your expertise and guidance have been a game-changer for me. Your ability to explain complex investing concepts in a clear and concise way has given me the confidence to take control of my financial future.
I'm grateful for your support and wisdom!
For better analysis and trading success I highly recommend Susan Brookes for the job as your personal coach
She head a group network of people that help share thrilling and life changing tutorial which helps us navigate the problems in trading
She's always active On her Email susandemorirs@gmail.com and 👍 WhatsApp +1 (472) 218-4301 for more information about her still her

0
Reply
User avatar and name identifying the post author
Gentleman1217
02/24
@KAYLA Yessir
0
Reply
User avatar and name identifying the post author
Elichotine
02/24
OMNI's data drop could pump $SGHT hard
0
Reply
User avatar and name identifying the post author
West-Bodybuilder-867
02/24
@Elichotine Do you think it'll pump soon?
0
Reply
User avatar and name identifying the post author
MarshallGrover
02/24
Glaucoma game changing, Sight Sciences printing 💰💰
0
Reply
User avatar and name identifying the post author
Traditional_Wave8524
02/24
META-analysis hype, but real-world data's the gem
0
Reply
User avatar and name identifying the post author
Outrageous-Rate-4080
02/24
OMNI's data drop at AGS might shake up $SGHT stock. Keep eyes peeled, glaucoma game changing. 🚀
0
Reply
User avatar and name identifying the post author
TheLastMemeLeft
02/25
@Outrageous-Rate-4080 Do you think it'll pump hard?
0
Reply
User avatar and name identifying the post author
aiolyfe
02/24
OMNI's data drop at AGS might shift glaucoma game; keep eyes peeled, folks. 🚀
0
Reply
User avatar and name identifying the post author
therealchengarang
02/24
MIGS tech is hot. OMNI's implant-free approach could be a game-changer. I'm bullish on Sight Sciences.
0
Reply
User avatar and name identifying the post author
ZhangtheGreat
02/25
@therealchengarang What do you think about the competition?
0
Reply
User avatar and name identifying the post author
PunishedRichard
02/24
AGS 2025 is like a glaucoma summit. OMNI's presentations could make waves in the eyecare world.
0
Reply
User avatar and name identifying the post author
throwaway0203949
02/24
@PunishedRichard Think OMNI could moon after AGS?
0
Reply
User avatar and name identifying the post author
Bothurin
02/25
@PunishedRichard Totally agree, OMNI's data drop could pump the stock.
0
Reply
User avatar and name identifying the post author
nicpro85
02/24
Sight Sciences' move: reduce meds, improve life quality.
0
Reply
User avatar and name identifying the post author
Sugamaballz69
02/24
2,379 eyes, 36 months data? That's solid evidence for glaucoma treatment. OMNI's consistency is impressive.
0
Reply
User avatar and name identifying the post author
mav101000
02/24
Holding $SGHT long, MIGS tech is future
0
Reply
User avatar and name identifying the post author
gnygren3773
02/24
GEMINI study is a big deal. Sight Sciences might be setting a new standard for glaucoma treatment.
0
Reply
User avatar and name identifying the post author
confused-student1028
02/24
Real-world data from IRIS Registry is gold. OMNI's performance across diverse patients is something to watch closely.
0
Reply
User avatar and name identifying the post author
RadioactiveCobalt
02/24
Sight Sciences' commitment to advancing glaucoma care is evident. Future looks bright for OMNI and beyond.
0
Reply
User avatar and name identifying the post author
Phuffu
02/24
Mosaed's META-analysis could be a game-changer. Reducing IOP with less meds is a win-win.
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App